Wholesale Powder New Raws Peptide Loss Fat Retatrutide Injection Vials 5mg/10mg/15mg

Products Name: Retatrutide
CAS No.: 2381089-83-2
Purity: >99.0%
Molecular Formula: C221H342N46O68
Molecular Weight: 4731.33 g/mol
Sequence: 

          Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-

          Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-

          Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-

          Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-

          Pro-Pro-Pro-Ser-NH2

Appearance: White Lyophilized powder
Reconstitution: Required 
Storage:After reconstitution store at 2°C - 8°C

Product Function:

• Helps slow food leaving your stomach
• Helps prevent your liver from making too much sugar
• Helps the pancreas produce more insul when your blood sugar levels are high
• Can help control blood glucose
• Can reduce hyperglycemia, especially after meals
• Can reduce fasting insul and fasting glucose
• Can reduce hemoglobin A1c
• Can decrease appetite and caloric intake, while inhibiting weight gain
• Has been shown to lower triglyceride levels and oxidative stress from high LDL
• Has been shown to help induce weight loss in obese patients with higher dosing
• Helps decrease leptin and increase leptin sensitivity
• Can increase the conversion of white fat to brown fat                                                                                                 
• How is Retatrutide different from Semaglutide and Trizepatide ?  
   Weight loss in trials:
  1. Semaglutide led to a 6-12% reduction in body weight in 28 weeks
  2. Tirezepatide led to a 15-20% reduction in body weight in 72 weeks
  3. Retatrutide led to a 25% reduction in body weight in 48 weeks
  
   Weight Management
  Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia)
  Initiate with low dose and gradually escalate to maintenance dose of 2.4 mg/week SC to minimize GI adverse reactions
  If unable to tolerate a dose during escalation, consider delaying dose escalation for 4 weeks
  If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once-weekly; discontinue if not tolerated after second attempt
  In patients with type 2 diabetes, monitor blood glucose before initiating and during treatment
   Once weekly SC dose escalation schedule:
  Weeks 1-4: 0.25 mg
  Weeks 5-8: 0.5 mg
  Weeks 9-12: 1 mg
  Week 13-16: 1.7 mg
  Week 17 and onward: 2.4 mg (maintenance)
• 1 Semaglutide work as (GLP-1) hormone agonist.
  2. Tirezepatide work as (GLP-1 & GIP ) hormone agonist.
  3. Retatrutide work as (GLP-1 & GIP & Glucagon) hormones agonist.

GENERIC PEPTIDES (GMP)

#	Product	Sequence	Therapeutic Area	Form	Unit Size
4109712	Semaglutide CAS No.: 910463-68-2	H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH	Type II diabetes mellitus Obesity	Lyophilized powder	2 mg/vial 5 mg/vial 10 mg/vial 15 mg/vial 20 mg/vial 1 g/tube
4109713	Tirzepatide CAS No.: 2023788-19-2	H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2	Type II diabetes mellitus Obesity	Lyophilized powder	10 mg/vial 15 mg/vial 20 mg/vial 30 mg/vial 60 mg/vial 1 g/tube
4109714	Cagrilintide CAS No.: 1415456-99-3	{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2	Type II diabetes mellitus Obesity	Lyophilized powder	5 mg/vial 10 mg/vial 1 g/tube
4109715	CagriSema	Blend	Type II diabetes mellitus Obesity	Lyophilized powder	5 mg/vial 10 mg/vial 20 mg/vial 1 g/tube
4109716	Retatrutide CAS No. 2381089-83-2	Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2	Treatment of type 2 diabetes Treatment of obesity	Lyophilized powder	8 mg 10 mg 12 mg 15 mg 1 g/tube

 

Our Advantages: High purity, Wholesale price, large stock, Stealth Shipping, 100% Delivery Guarantee

 

Company

 

Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (cGMP) standards.

Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle. 

Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation.  LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean room

Packaging & Shipping

FAQ

1. How to preserve peptides after receiving them?
Peptides in the form of lyophilized powder can be transported at room temperature by vacuum packaging, while polypeptides in the dissolved state need to be refrigerated at 2°C - 8°C. For long-term storage, peptides should be stored in the form of lyophilized powder stored at -20°C or -80°C in a sealed container with desiccant, which can avoid the degradation of peptides to the greatest extent.
 

5. Will I have any side effects after using peptide?
If you just begin to use, it is better to follow doctor's prescription. And if there is no allergy or any uncomfortable symptom, you can continue to use but take it in a suitable dosage. A few people will have slight allergy reaction, but after your body get used to it, the allergy will be disappear and back to normal.